A Randomised, Placebo Controlled, Four-way Cross-over Study to Assess Cardiac Re-polarisation Following Repeat Dosing With GSK2190915 and Placebo for Five Days, With Moxifloxacin as a Positive Control, in Healthy Male and Female Subjects.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 20 Aug 2013
At a glance
- Drugs Fiboflapon (Primary) ; Moxifloxacin
- Indications Asthma
- Focus Pharmacodynamics
- 20 Aug 2013 Status changed from suspended to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 08 Dec 2012 Planned End Date changed to 1 Dec 2014.
- 08 Dec 2012 New trial record